Abstract Library

#1425 Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.

Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Lucas C, Goodman S, Smith J, Burge M, Wyld D,

Keywords: lutetium, dosimetry, renal, gelatin, somatostatin,

#341 Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results

Introduction: In previous phase II studies of EVE in patients with pNET, those with elevated baseline Chromogranin A (eCgA) and neuron-specific enolase (eNSE) levels experienced shorter PFS.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Oberg K, Anthony L, Sideris L, Chen L, Cherfi A,

Keywords: mTOR, everolimus, chromogranin A, neuron-specific enolase, pancreatic neuroendocrine tumors,